Role of VEGF inhibition in the treatment of retinopathy of prematurity

Seminars in Ophthalmology

Volumn 31, Issue 1-2, 2016, Pages 163-168

  Eldweik, Luai ^a   Mantagos, Iason S ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Extremely low birth weight infants; Oxygen saturation; Prematurity; Retinopathy of prematurity; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; PEGAPTANIB; RANIBIZUMAB; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ASTIGMATISM; CAPILLARY DENSITY; CIRCULATION; DRUG ABSORPTION; DRUG EFFICACY; EXTREMELY LOW BIRTH WEIGHT; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; HYPEROXIA; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LOW LEVEL LASER THERAPY; NONHUMAN; OXYGEN SATURATION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN FUNCTION; RESUSCITATION; RETINA BLOOD VESSEL; RETINA FLUORESCEIN ANGIOGRAPHY; RETROLENTAL FIBROPLASIA; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; INFANT; INTRAVITREAL DRUG ADMINISTRATION; NEWBORN; RETINOPATHY OF PREMATURITY;

ANGIOGENESIS INHIBITORS; HUMANS; INFANT; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84962132697     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2015.1114847     Document Type: Review

References (65)

1. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol 1988;106: 471-479.
2. Palmer EA, Hardy RJ, Dobson V, et al. Cryotherapy for Retinopathy of Prematurity Cooperative Group. 15-Year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 2005;123: 311-318.
3. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-16894.
4. Ells AL, Holmes JM, Astle WF, et al. Telemedicine approach to screening for severe retinopathy of prematurity: A pilot study. Ophthalmology 2003;110: 2113-2117.
5. Photographic Screening for Retinopathy of Prematurity Study (PHOTO-ROP) Cooperative Group. The photographic screening for retinopathy of prematurity study (photo-ROP). Primary outcomes. Retina 2008;28: S47-S54.
6. McNamara JA, Tasman W, Vander JF, Brown GC. Diode laser photocoagulation for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1992; 110:1714-1716.
7. Capone Jr A, Diaz-Rohena R, Sternberg Jr P, et al. Diodelaser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol 1993;116:444-450.
8. Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study. Ophthalmology 1993;100:238-244.
9. Banach MJ, Ferrone PJ, Trese MT. A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 2000; 107:324-328.
10. Prenner JL, Capone Jr A, Trese MT. Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology 2004;111:2271-2273.
11. Capone Jr A, Trese MT. Lens-sparing vitreous surgery for tractional stage 4A retinopathy of prematurity retinal detachments. Ophthalmology 2001;108:2068-2070.
12. Hubbard III GB, Cherwick DH, Burian G. Lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Ophthalmology 2004;111:2274-2277.
13. Kychenthal A, Dorta P. 25-Gauge lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Retina 2008;28: S65-S68.
14. Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991-1915.
15. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
16. Bossi E, Koerner F. Retinopathy of prematurity. Intens Care Med 1995;21:241-246.
17. Berkowitz BA, Penn JS. Abnormal panretinal response pattern to carbogen inhalation in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 1998;39:840-845.
18. Gu X, El-Remessy AB, Brooks SE, et al. Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite. Am J Physiol Cell Physiol 2003;285: C546-C554.
19. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
20. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114: 1219-1228.
21. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division: evidence that 'physiological hypoxia' is the stimulus for normal retinal development. Invest Ophthalmol Vis Sci 1995;36:1201-12014.
22. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133-140.
23. Stevens TP, Finer NN, Carlo WA, Szilagyi PG, et al. Respiratory outcomes of the Surfactant Positive Pressure and Oximetry Randomized Trial (SUPPORT). J Pediatr 2014;165:240. e4-249. e4.
24. Khadawardi E, Al Hazzani F. Oxygen saturation and outcomes in preterm infants, The BOOST II United Kingdom, Australia, and New Zealand Collaborative Groups. J Clin Neonatol 2013;2:73-75.
25. Askie LM, Brocklehurst P, Darlow BA, et al. NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol. BMC Pediatr 2011;11:6.
26. Leone TA, Rich W, Finer NN. A survey of delivery room resuscitation practices in the United States. Pediatrics 2006; 117:e164-e175.
27. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738-4747.
28. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1: 182-193.
29. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538-1544.
30. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009; 116:1599-1603.
31. Hartnett ME. Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2010;108:96-119.
32. FDA approves new drug treatment for age-related macular degeneration. http://www. fda. gov/NewsEvents/ Newsroom/PressAnnouncements/2004/ucm108385. htm.
33. Autrata R, Krejcirova I, Senkova K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 2012;22:687-694.
34. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol 2012;22(5):685-686.
35. Menke MN, Framme C, Nelle M, et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol 2015;15:20.
36. Mota á, Carneiro Â, Breda J, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol 2012;3:136-141.
37. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 2008;92(5):667-668.
38. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603-615.
39. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis. Ophthalmology 2015;122: 1008-1015.
40. Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013;155: 1119. e1-1124. e1.
41. Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 2014;121:2212-2219.
42. Tahija SG, Hersetyati R, Lam GC, et al. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 2014;98: 507-512.
43. Castellanos MA, Schwartz S, Garcá-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 2013;97:816-819.
44. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular agerelated macular degeneration. Retina 2006;26:859-870.
45. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-2823.
46. Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 2002;9:152-166.
47. Ehlers N, Mathiesen ME, Andersen H. The prenatal growth of the human eye. Acta Ophthalmol (Copenh) 1968; 46:329-349.
48. Larsen JS. The sagittal growth of the eye. Acta Ophthalmol 1971;49:441-444.
49. Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol 2014;92:577-581.
50. Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina 2011;31:161-168.
51. Chuang LH, Wu WC, Yeung L, et al. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion. Ophthalmic Res 2011;45:31-35.
52. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111: 707-716.
53. Hislop AA, Wigglesworth JS, Desai R. Alveolar development in the human fetus and infant. Early Hum Dev 1986; 13:1-11.
54. Thebaud B. Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neonatology 2007;91:291-297.
55. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 2002;8:702-710.
56. Sentilhes L, Marret S, Leroux P, et al. Vascular endothelial growth factor and its high-affinity receptor (VEGFR-2) are highly expressed in the human forebrain and cerebellum during development. J Neuropathol Exp Neurol 2010;69: 111-128.
57. Spandau U. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Acta Ophthalmol 2013;91:e154.
58. Hård A-L, Smith LE, Hellström A. Nutrition, insulin-like growth factor-1 and retinopathy of prematurity. Semin Fetal Neonatal Med 2013: S1744165X13000073.
59. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5:1390-1395.
60. Hellström A, Engström E, Hård AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003;112:1016-1020.
61. Ley D1, Hansen-Pupp I, Niklasson A, et al. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatr Res 2013;73:68-74.
62. Nakano M, Satoh K, Fukumoto Y, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007; 100:662-669.
63. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014;4: CD004863.
64. Pieh C, Agostini H, Buschbeck C, et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 2008;92:689-6893.
65. Jiang Y, Wang H, Culp D, et al. Targeting Müller Cell-Derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2014;55:824-831.